A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

Autism Spectrum Disorder Clinical Trial

Official title:

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05733390
• Other study ID #: JZP541-201
• Secondary ID: 2022-502355-61-0
• Status: Terminated
• Phase: Phase 2
• Start date: June 30, 2023
• Est. completion date: November 9, 2023

Study information

• Verified date: December 2023
• Source: Jazz Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Behavior dysregulation is commonly associated with people with autism spectrum disorder (ASD). Irritability is a major safety concern in adults with ASD. This study will assess the efficacy and safety of JZP541 in the treatment of adults with irritability associated with ASD.

Description:

This randomized, double-blind, placebo-controlled, phase 2 study will evaluate the efficacy and safety of JZP541 in treating irritability in adults with ASD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: November 9, 2023
• Est. primary completion date: November 9, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male or female aged 18 to 45 years inclusive at the time of signing the informed consent

• Has a suitable study partner who keeps in regular contact with the participant, has sufficient knowledge of the participant's behavior to complete the study assessments, able to communicate with site personnel, willing to comply with protocol requirements, and has adequate literacy to complete the protocol-specified questionnaires

• Participant has full scale intelligence quotient (IQ) or General Ability Index (GAI) >45, measured in adulthood using the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) or Wechsler Adult Intelligence Scale - Second Edition (WASI-II), and the ability to self-report on adverse events (AEs) as determined by the investigator

• Able to cooperate and take part in study assessments, including blood sampling

• Has a current diagnosis of autism spectrum disorder (ASD) as per DSM-5 criteria for ASD [confirmed at screening], which has been confirmed by the Autism Diagnostic Observational Schedule-2nd Edition (ADOS-2) or the Autism Diagnostic Interview-Revised (ADI-R) [lifetime assessment is acceptable]. If no lifetime assessment is available, the ADOS-2 or ADI-R should be performed at screening for diagnosis confirmation

• Has episodes of temper outbursts, aggression, self-injurious behavior or a combination of these issues that interfere with the participant's performance or affect others

• Participant's irritability per Clinical Global Impression of Severity (CGIS) is at least 3 (moderate) at screening and randomization

• All medications taken by the participant that may have an effect on ASD symptoms, behavior, anxiety, or sleep must have been stable for 4 weeks, or 8 weeks for long-acting formulations, prior to the Screening Visit and Visit 2

• Willing to maintain a stable regimen for all participant medications and interventions throughout the study

• Participant is compliant with their current medications

• Male participants must agree to refrain from donating sperm, or be abstinent, or agree to use contraception during the Study Intervention Period and for at least 12 weeks after the last dose of study intervention

• Female participants are eligible if she is not pregnant or breastfeeding as specified

• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 14 days before the first dose of study intervention

• Participant (or study partner) is willing and able to give informed consent or assent

Exclusion Criteria:

• Has a severe or profound intellectual disability (ie, IQ or GAI = 45)

• Participant is unable to self-report AEs, as determined by the investigator

• Has a current diagnosis of psychosis spectrum disorders (bipolar disorder with psychotic features, schizo-affective disorder, delusional disorder, or schizophrenia)

• Has a current diagnosis of major depression (participants with depression in remission for at least 12 months may be included)

• Has an established history of psychotic spectrum disorders, early signs of psychosis at screening or Visit 2, or first degree relative with a lifetime diagnosis of psychosis spectrum disorders

• Has had a seizure within the past 2 years

• Has had changes in anticonvulsive therapy within the last 12 weeks

• Has experienced myocardial infarction or clinically significant cardiac dysfunction within the 12 months prior to Visit 1 or has a history of clinically significant arterial vascular disease, including cerebrovascular and cardiovascular disease

• Has supine systolic blood pressure < 90 mmHg or > 150 mmHg or supine diastolic blood pressure < 50 mmHg or > 105 mmHg or a postural drop in systolic blood pressure = 20 mmHg or diastolic blood pressure = 10 mmHg, with or without symptoms, at screening or baseline (prior to randomization)

• Has a QTcF interval > 450 ms or a history of additional risk factors for Torsades de pointes

• Has any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, may influence the result of the study, or may affect the participant's ability to take part in the study

• Had in the 2 weeks prior to screening or up to randomization any condition that might affect baseline assessments

• Has received administration of strong inducers of CYP3A4 = 14 days prior to first doses of study intervention or have ongoing requirements for these medications

• Is currently using or has used within the 12 weeks prior to screening recreational or medicinal cannabis, cannabinoid-based medications (botanical or synthetic; eg, Sativex, Epidiolex/Epidyolex, Nabilone, Dronabinol) and/or is unwilling to abstain for the duration of the study

• Is currently taking bupropion

• Has received another investigational product within the 12 weeks prior to the Screening Visit

• Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention

• Has been previously randomized into this study

• Has impaired liver function at screening, as reflected by serum alanine aminotransferase or aspartate aminotransferase > 1.5 × ULN, or total bilirubin > ULN

• Female participant who is pregnant (positive pregnancy test), lactating, or planning pregnancy during the study or within 3 months thereafter

• Has any history of suicidal behavior or any suicidal ideation (with intent per C-SSRS questions 4 and 5) in the last month at screening (last month) or Visit 2 (randomization)

• Has any known or suspected history of alcohol or substance abuse

• Has positive drug abuse test at screening

• Is living in the same household as another active participant of this study or nominated study partner is actively serving as a study partner for another participant of this study (Note: Same household does not apply to professional care-home environment)

Related Conditions & MeSH terms

• ASD
• Autism Spectrum Disorder
• Autistic Disorder
• Child Development Disorders, Pervasive
• Irritability Associated With Autism Spectrum Disorder

Intervention

Drug:
• JZP541
Oral suspension

Other:
• Placebo
Oral suspension

Locations

Country	Name	City	State
United States	Albert Einstein College of Medicine	Bronx	New York

Sponsors (2)

Lead Sponsor	Collaborator
Jazz Pharmaceuticals	GW Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change From Baseline to Week 12 in the Aberrant Behavior Checklist-Irritability (ABC-I) Subscale Score	The ABC-I subscale contains 15 items and its score is used to rate a person's irritability over the past 7 days on a 4-point scale, where 0 indicates no irritability and 3 indicates severe irritability. Higher scores indicate worse outcome.	Baseline to Week 12
Secondary	Number of Participants With Treatment-emergent Adverse Events		Day 1 up until end of study or discontinuation (whichever occurs first), up to approximately 2 years
Secondary	Percentage of Participants with = 25% Reduction in Aberrant Behavior Checklist-Irritability (ABC-I) Subscale Score From Baseline	The ABC-I subscale contains 15 items and its score is used to rate a person's irritability over the past 7 days on a 4-point scale, where 0 indicates no irritability and 3 indicates severe irritability. Higher scores indicate worse outcome.	Baseline up until end of study or discontinuation (whichever occurs first), up to approximately 2 years
Secondary	Mean Change in ABC-I Score After Treatment Discontinuation	The ABC-I subscale contains 15 items and its score is used to rate a person's irritability over the past 7 days on a 4-point scale, where 0 indicates no irritability and 3 indicates severe irritability. Higher scores indicate worse outcome.	Date of treatment discontinuation up until end of study or discontinuation (whichever occurs first), up to approximately 2 years
Secondary	Mean Change From Baseline in the Caregiver Top 3 ABC-I Items of Concern		Baseline up until end of study or discontinuation (whichever occurs first), up to approximately 2 years
Secondary	Mean Change From Baseline to Week 12 in Aberrant Behavior Checklist (ABC) Modified Social Withdrawal Subscale Score	The ABC Modified Social Withdrawal subscale contains 13 items and its score is used to rate a person's social withdrawal over the past 7 days on a 4-point scale, where 0 indicates no withdrawal and 3 indicates severe/extreme social withdrawal. Higher scores indicate worse outcome.	Baseline to Week 12
Secondary	Mean Change From Baseline to Week 12 in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score	The ABC Stereotypic Behavior subscale contains 7 items and its score is used to rate a person's stereotypic behavior over the past 7 days on a 4-point scale, where 0 indicates no stereotypic behavior and 3 indicates severe stereotypic behavior. Higher scores indicate worse outcome.	Baseline to Week 12
Secondary	Mean Change From Baseline to Week 12 in Repetitive Behavior Scale - Revised (RBS-R) Subscale Scores	The RBS-R subscale score is used to rate a person's behavior over the past 7 days on a 4-point scale, where 0 indicates that the behavior does not occur and 3 indicates that the behavior occurs and is a serious problem. Higher scores indicate worse behavior.	Baseline to Week 12